ESC 2025: Real-world study highlights superior efficacy profile of GLP-1RAs
On 29 August, at the 75th European Society of Cardiology (ESC) conference, during a moderated poster session on the topic …
Post
-
-
BioXCel seeks Igalmi label expansion after Phase III success
BioXCel Therapeutics is applying for a label expansion to the outpatient setting for its key schizophrenia and bipolar asset, Igalmi …
-
Driving clinical research progress through innovation and patient engagement
In September 2025, leading professionals across the biotech and pharmaceutical industries will gather and discuss solutions to exchange insights about …
-
UK MHRA to initiate pilot for clinical trials
The UK Medicines and Healthcare products Regulatory Agency (MHRA) is set to launch a pilot aimed at refining the approval …
-
Amgen partners with Veeva Systems to enhance clinical trial processes
Amgen has entered a partnership to use Veeva Systems’ comprehensive Clinical Platform to enhance trial processes. This collaboration also aims to …
-
Podcast: Migration of clinical studies
Migrating clinical studies to a new platform requires careful planning and is the focus of episode four in the Zelta …
-
Eli Lilly’s Verzenio boosts OS in breast cancer as Novartis rivalry heats up
Pharmaceutical giant Eli Lilly has boasted positive topline results from its primary analysis of a Phase III trial with breast …
-
Wugen raises $115m for trial of T-cell cancer therapy
US-based biotechnology company Wugen has completed a $115m equity financing round to fund the company's T-RRex trial of CAR-T therapy, …
-
RemeGen secures telitacicept Phase III win in IgAN, seeks China approval
RemeGen will apply for telitacicept’s approval in China for the treatment of immunoglobulin-A nephropathy (IgAN) after the drug met its …
-
PCM Trials, EmVenio Research, and Clinical Trial Service rebrand as EmVenio Clinical Research
PCM Trials, along with its subsidiaries EmVenio Research and Clinical Trial Service, are aligning under a single name – EmVenio …
-
MSD and Daiichi Sankyo commence Phase III breast cancer therapy trial
MSD and Daiichi Sankyo have initiated the Phase III HERTHENA-Breast04 clinical trial, with the first subject receiving a dose of …
-
Clinical Trials Arena Excellence Awards 2025: Beaconcure
In the world of clinical trials, the pressure to make clinical data review more efficient, foster better teamwork, and keep …
-
Amylyx culls rare neurological disorder programme after trial failure
Amylyx Pharmaceuticals has discontinued a clinical programme evaluating a neuronal cell death inhibitor as a result of disappointing data when tested …
-
Regeneron tees up myasthenia gravis drug approval after Phase III victory
Regeneron is eyeing regulatory approval for its subcutaneous generalised myasthenia gravis (gMG) candidate cemdisiran after positive results from a Phase …
-
Eli Lilly eyes orforglipron approval after Phase III diabetes trial success
Although data for Eli Lilly’s orforglipron may have disappointed investors earlier this month, a new release of Phase III data …
